Anagrelide: A Clinically Effective cAMP Phosphodiesterase 3A Inhibitor with Molecular Glue Properties.

Published in: ACS medicinal chemistry letters (2023)

The mode of action by which the orphan drug anagrelide ( 1 ), a potent cAMP phosphodiesterase 3A inhibitor, reduces blood platelet count in humans is not well understood. Recent studies indicate that 1 stabilizes a complex between PDE3A and Schlafen 12, protecting it from degradation while activating its RNase activity.

Keyphrases

binding protein
signaling pathway
protein kinase
emergency department
single molecule
case control